EVLO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 21:55):

Stats
Dagens volum	22 122.00
Gjennomsnittsvolum	33 335.00
Markedsverdi	825 752
EPS	$0 ( 2024-03-21 )
Neste inntjeningsdato	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-07	Bodmer Mark	Buy	6 625	Common Stock
2023-11-08	Bodmer Mark	Sell	3 163	Common Stock
2023-11-07	Bodmer Mark	Sell	6 625	Restricted Stock Units
2023-11-07	Mchale Duncan	Buy	6 500	Common Stock
2023-11-08	Mchale Duncan	Sell	3 103	Common Stock

INSIDER POWER
86.63
Last 96 transactions
Buy: 11 679 076 \| Sell: 749 652

Evelo Biosciences Inc Korrelasjon

10 Mest positive korrelasjoner
YJ	0.981
RPTX	0.978
CLFD	0.977
LGMK	0.977
CREG	0.972
JAGX	0.971
CFRX	0.965
HOL	0.963
MMAT	0.963
SLNG	0.963

10 Mest negative korrelasjoner
BRIV	-0.986
ENTF	-0.986
ORIA	-0.984
PRLH	-0.984
PPYA	-0.984
IVCP	-0.983
HCNE	-0.983
PWUP	-0.983
BIOS	-0.983
CBRG	-0.983

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Evelo Biosciences Inc Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-26.28

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-26.28

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-3.09

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.37

Financial Reports:

No articles found.

Evelo Biosciences Inc

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Sanntidsoppdatering for Evelo Biosciences Inc [EVLO]

Upcoming Earnings Alert